Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Do female patients see their physicians differently? A population-based study evaluating perception of physician communication by patients with hidradenitis suppurativa

Harvey LF, Kingston P, Kikuchi R, Manasyan A, Sadrolashrafi K, Hao A, Tolson H, Yee D, Armstrong AW. Do female patients see their physicians differently?[...]

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin[...]

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition

Kokikian N, Tarabay J, Goh C. Scarring alopecia as an unexpected consequence of immune checkpoint inhibition. JAAD Case Rep. 2025 May 8;61:1-6. doi: 10.1016/j.jdcr.2025.04.007. PMID:[...]